Delivery Order SPE2DB20D2014-SPE2DB25FD05F
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,230.97 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Gemtesa (mirabegron) is a beta-3 agonist used to treat overactive bladder,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) under a firm fixed price contract valued at $3,328.73. The award, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies to...
- The Defense Logistics Agency awarded a delivery order valued at $9,932.61 to AmerisourceBergen Drug Corp for 90-tablet supplies of Gemtesa 75 mg tablets. This is a firm fixed price delivery order with an ultimate completion date of June 18, 2025, and represents a non-competitive set-aside delivery against AmerisourceBergen's larger contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,478.60 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 21, 2025, with a completion date of August 22, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $52,500.45. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $8,009.57 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity). This is a firm fixed-price, non-set-aside contract with a completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, was competitively selected...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,095.26 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $8,109.88. The award was made on July 18, 2025, with an ultimate completion date of July 21, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Gemtesa is a prescription...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,479.31 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count), with an ultimate completion date of September 4, 2025. The contract, awarded on September 3, 2025, utilizes firm fixed-price pricing under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count packaging) under a firm fixed-price contract valued at $2,679.22. The award, issued on July 3, 2025, with an ultimate completion date of July 7, 2025, represents a non-competitive procurement leveraging the company's existing contract vehicle. Performance of this delivery order will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FD05FDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract with a ceiling value of $30,228.09. This non-competitive, non-set-aside delivery order was executed on September 18, 2025, with an ultimate completion date of September 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Gemtesa (mirabegron) is a beta-3 adrenergic agonist commonly prescribed to treat overactive bladder, representing part of the company's broad portfolio of pharmaceutical products supplied to federal healthcare systems. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and active through December 2026. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, has demonstrated capability to serve military and veteran healthcare systems through competitive federal procurement. The company's extensive contract portfolio with the DLA encompasses a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.2k | 9/18/25 |